Dr Steven Eliot Weinstein, MD | |
3 Westbrook Rd, West Whately, MA 01039-9600 | |
(413) 665-8116 | |
Not Available |
Full Name | Dr Steven Eliot Weinstein |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 3 Westbrook Rd, West Whately, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1578776415 | NPI | - | NPPES |
3022358 | Medicaid | MA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | 47062 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Steven Eliot Weinstein, MD 3 Westbrook Rd, West Whately, MA 01039-9600 Ph: (413) 665-8116 | Dr Steven Eliot Weinstein, MD 3 Westbrook Rd, West Whately, MA 01039-9600 Ph: (413) 665-8116 |
News Archive
PPD, Inc. today announced it has expanded its cGMP laboratory testing services into Wayne, Pa., to meet growing client demand for these services from pharmaceutical and biotechnology companies located in the northeastern United States.
New research finds a dramatic increase in physical abnormalities in newborns caused by opioid exposure during pregnancy.
Many patients live with low back pain that radiates to the buttock, groin, thigh, and even knees. The challenge for patients, and often their doctors, is determining the origin of the pain - the hip, the spine, or both.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
› Verified 9 days ago